Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Sortilin gates neurotensin and BDNF signaling to control ...

Om AU

Sortilin gates neurotensin and BDNF signaling to control peripheral neuropathic pain

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

DOI

  • Mette Richner
  • Lone T Pallesen
  • Maj Ulrichsen, The Lundbeck Foundation Research Center MIND, Department of Biomedicine, Aarhus University, Aarhus, 8000 C, Denmark.
    • ,
  • Ebbe T Poulsen
    • ,
  • Thomas H Holm
    • ,
  • Hande Login
  • Annie Castonguay, Université Laval
    • ,
  • Louis-Etienne Lorenzo, Université Laval
    • ,
  • Nádia P Gonçalves
    • ,
  • Olav M Andersen
  • Karin Lykke-Hartmann
  • Jan J Enghild
  • Lars C B Rønn, Neurodegeneration Disease Biology Unit, H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark.
    • ,
  • Ibrahim J Malik, Neurodegeneration Disease Biology Unit, H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark.
    • ,
  • Yves De Koninck, Université Laval
    • ,
  • Ole J Bjerrum, Københavns Universitet
    • ,
  • Christian B Vægter
  • Anders Nykjær

Neuropathic pain is a major incurable clinical problem resulting from peripheral nerve trauma or disease. A central mechanism is the reduced expression of the potassium chloride cotransporter 2 (KCC2) in dorsal horn neurons induced by brain-derived neurotrophic factor (BDNF), causing neuronal disinhibition within spinal nociceptive pathways. Here, we demonstrate how neurotensin receptor 2 (NTSR2) signaling impairs BDNF-induced spinal KCC2 down-regulation, showing how these two pathways converge to control the abnormal sensory response following peripheral nerve injury. We establish how sortilin regulates this convergence by scavenging neurotensin from binding to NTSR2, thus modulating its inhibitory effect on BDNF-mediated mechanical allodynia. Using sortilin-deficient mice or receptor inhibition by antibodies or a small-molecule antagonist, we lastly demonstrate that we are able to fully block BDNF-induced pain and alleviate injury-induced neuropathic pain, validating sortilin as a clinically relevant target.

OriginalsprogEngelsk
Artikelnummereaav9946
TidsskriftScience Advances
Vol/bind5
Nummer6
Antal sider13
ISSN2375-2548
DOI
StatusUdgivet - 19 jun. 2019

Se relationer på Aarhus Universitet Citationsformater

ID: 157139667